Novartis’ generic unit Sandoz has sued United Therapeutics for what it calls anticompetitive behavior over its copies of United’s Remodulin. Novartis says United placed “artificial restrictions” on cartridges needed for intravenous delivery of the pulmonary arterial hypertension drug. In the pharmacy benefit, Remodulin holds preferred-tier access for 10% of covered lives, and is not covered for 19% of lives.

SOURCE: MMIT Analytics, as of 4/22/19